The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis

2018 Levi, 2008, The changing pattern of kidney cancer incidence and mortality in Europe, BJU Int, 101, 949, 10.1111/j.1464-410X.2008.07451.x Patard, 2002, Prognostic significance of the mode of detection in renal tumours, BJU Int, 90, 358, 10.1046/j.1464-410X.2002.02910.x Ljungberg, 2015 Sun, 2011, Prognostic factors and predictive models in renal cell carcinoma: a contemporary review, Eur Urol, 60, 644, 10.1016/j.eururo.2011.06.041 Bourdon, 2007, p53 and its isoforms in cancer, Br J Cancer, 97, 277, 10.1038/sj.bjc.6603886 Bui, 2001, Prognostic factors and molecular markers for renal cell carcinoma, Expert Rev. Anticancer Ther, 1, 565, 10.1586/14737140.1.4.565 Gad, 2007, Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma, Br J Cancer, 96, 336, 10.1038/sj.bjc.6603492 Noon, 2010, p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?, Cancer, 116, 780, 10.1002/cncr.24841 Hafsi, 2013, Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53, BMC Cancer, 13, 134, 10.1186/1471-2407-13-134 Bourdon, 2014, p53 isoforms change p53 paradigm, Mol Cell Oncol, 1 Joruiz, 2016, p53 isoforms: key regulators of the cell fate decision, Cold Spring Harb Perspect Med, 6, 10.1101/cshperspect.a026039 Khoury, 2011, p53 isoforms: an intracellular microprocessor?, Genes Cancer, 2, 453, 10.1177/1947601911408893 Bourdon, 2007, p53 Family isoforms, Curr Pharm Biotechnol, 8, 332, 10.2174/138920107783018444 Machado-Silva, 2010, p53 family members in cancer diagnosis and treatment, Semin Cancer Biol, 20, 57, 10.1016/j.semcancer.2010.02.005 Khoury, 2010, The isoforms of the p53 protein, Cold Spring Harb Perspect Biol, 2, 10.1101/cshperspect.a000927 Ghosh, 2004, Regulation of human p53 activity and cell localization by alternative splicing, Mol Cell Biol, 24, 7987, 10.1128/MCB.24.18.7987-7997.2004 Flaman, 1995, A simple p53 functional assay for screening cell lines, blood, and tumors, Proc Natl Acad Sci, 92, 3963, 10.1073/pnas.92.9.3963 Monti, 2011, Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes, Mol Cancer Res, 9, 271, 10.1158/1541-7786.MCR-10-0496 Andreotti, 2011, p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screeningsystem, PLoS One, 6, e20643, 10.1371/journal.pone.0020643 Rivlin, 2011, Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis, Genes Cancer, 2, 466, 10.1177/1947601911408889 Bourdon, 2005, p53 isoforms can regulate p53 transcriptional activity, Genes Dev, 9, 1 Takahashi, 2013, p53 isoform profiling in glioblastoma and injured brain, Oncogene, 32, 3165, 10.1038/onc.2012.322 van den Berg, 2010, Regulation of p53 isoform expression in renal cell carcinoma, Front Biosci, 2, 1042 Song, 2009, Expression of p53 isoforms in renal cell carcinoma, Chin Med J (Engl), 122, 921 Sejima, 1999, Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma, Eur Urol, 35, 242, 10.1159/000019855 Zigeuner, 2004, Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue, Urology, 63, 651, 10.1016/j.urology.2003.11.011 Marabese, 2008, Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer, Eur J Cancer, 44, 131, 10.1016/j.ejca.2007.10.011 Boldrup, 2007, Expression of p53 isoforms in squamous cell carcinoma of the head and neck, Eur J Cancer, 43, 617, 10.1016/j.ejca.2006.10.019 Slee, 2004, To die or not to die: how does p53 decide?, Oncogene, 23, 2809, 10.1038/sj.onc.1207516 Marcel, 2010, p53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter, Oncogene, 29, 2691, 10.1038/onc.2010.26